Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials

Lee, Anne W.M.; Tung, Stewart Y.; Ngan, Roger K.C.; Chappell, Rick; Chua, Daniel T.T.; Lu, Tai Xiang; Siu, Lillian L.; Tan, Terence; Chan, L.K.; Ng, Wai Tong; Leung, TW; Fu, Yiu-Tung; Au, Gordon K.H.; Zhao, Chong; O’Sullivan, Brian; Tan, Eng‐Huat; Lau, W.S.

doi:10.1016/j.ejca.2010.10.026

Cited by 195 publications

(161 citation statements)

References 23 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Radiotherapy is the primary treatment for patients with non-metastatic NPC, and concurrent chemoradiotherapy is considered the standard treatment for locally-advanced NPC (1,2). Due to radioresistance, certain patients with NPC present with local recurrences and distant metastases 1-2 years after treatment (3).…”

Section: Introductionmentioning

confidence: 99%

Protein expression of nucleophosmin, annexin A3 and nm23-H1 correlates with human nasopharyngeal carcinoma radioresistance in vivo

Liang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Radioresistance is a significant obstacle in the treatment of endemic nasopharyngeal carcinoma (NPC). The present study aimed to identify proteins associated with radioresistance in NPC in vitro and in vivo. Proteomics analyses were conducted to screen for differentially-expressed proteins (DEPs) in parental CNE-2 cells and CNE-2R cells. Using proteomics approaches, 16 DEPs were identified. Of these DEPs, nucleophosmin (NPM1), annexin A3 and nm23-H1, were verified using western blot analyses. The tumorigenicity was investigated using mouse xenograft tumorigenicity assays, and tumor growth curves were generated. The protein expression of NPM1, annexin A3 and nm23-H1 was examined by immunohistochemically staining tumor tissues. NPM1 and annexin A3 protein levels were downregulated in the CNE-2R cells, whereas nm23-H1 expression was upregulated. In vivo tests showed that compared with the CNE-2 tumors, CNE-2R tumor growth was significantly retarded (P<0.05). CNE-2 tumor progression was inhibited by irradiation, but CNE-2R tumor progression was not, indicating that the CNE-2R cells were also radioresistant in vivo. NPM1 and annexin A3 expression was significantly lower in non-irradiated (NIR)-CNE-2R tumors compared with NIR-CNE-2 tumors (P<0.01). However, Nm23-H1 protein levels were significantly higher (P<0.05). Overall, the present study established comparable radioresistant and radiosensitive tumor models of human NPC, and identified candidate biomarkers that may correlate with radioresistance. The data showed that dysregulation of NPM1, annexin A3 and nm23-H1 expression correlated with the cellular and tumor radioresponse. These proteins are involved in the regulation of intracellular functions, including stress responses, cell proliferation and DNA repair. However, further clinical evaluations are required.

show abstract

Section: Introductionmentioning

confidence: 99%

Protein expression of nucleophosmin, annexin A3 and nm23-H1 correlates with human nasopharyngeal carcinoma radioresistance in vivo

Liang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…It has been confirmed that the dose intensity of cisplatin during CCRT confers survival benefit in head and neck squamous cell cancer (HNSCC). However, data on the total cisplatin dose during CCRT for NPC are limited [16,17]. …”

Section: Introductionmentioning

confidence: 99%

Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area

Wei

Huang

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

Background: We retrospectively compared the long-term efficacy of concurrent chemoradiotherapy (CCRT) regimens (docetaxel vs. cisplatin), total dose intensity of cisplatin (> 200 vs. ≤ 200 mg/m²) and pretreatment plasma levels of Epstein-Barr virus (EBV) DNA for nasopharyngeal carcinoma (NPC), and investigated the prognostic factors. Methods: We enrolled 214 patients diagnosed with NPC and treated with CCRT. 41 patients received weekly docetaxel and 173 weekly cisplatin. 62 received cumulative cisplatin of ≤ 200 mg/m² and 111, > 200 mg/m². Pretreatment levels of EBV DNA were available for 155 patients. Results: Patients receiving concurrent weekly docetaxel and cisplatin had similar 5-year rates for overall survival (OS) (p = 0.306), progression-free survival (PFS) (p = 0.133), distant failure-free survival (DFS) (p = 0.110), and locoregional failure-free survival (LFS) (p = 0.452). Cumulative cisplatin of > 200 mg/m² improved the 5-year rates of PFS (p = 0.018) and DFS (p = 0.042) significantly in comparison with cumulative cisplatin of ≤ 200 mg/m². EBV DNA levels of ≥ 1,500 copies/ml was closely associated with poor DFS (p = 0.011), PFS (p = 0.006), and OS (p = 0.004). Conclusions: Weekly cisplatin was well tolerated in CCRT, during which cumulative cisplatin of > 200 mg/m² improved PFS and DFS. The long-term efficacy of concurrent docetaxel was similar to that of concurrent cisplatin. The EBV DNA level was the most significant prognostic factor.

show abstract

“…The 5-year overall survival rate for NPC has increased from approximately 50% to 75% over the last ten years [13][14][15]. Advances in diagnostic technology, radiotherapy techniques and the introduction of combined chemotherapy are obvious, important contributors to this achievement [16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Maximum Primary Tumor Diameter in Nasopharyngeal Carcinoma

Chen

Liang

Deng

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials

Cited by 195 publications

References 23 publications

Protein expression of nucleophosmin, annexin A3 and nm23-H1 correlates with human nasopharyngeal carcinoma radioresistance in vivo

Protein expression of nucleophosmin, annexin A3 and nm23-H1 correlates with human nasopharyngeal carcinoma radioresistance in vivo

Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area

Prognostic Significance of Maximum Primary Tumor Diameter in Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About